Hypomethylating agent versus venetoclax combination: an electronic health records-based target trial emulation among Asian elderly patients with newly diagnosed acute myeloid leukaemia in Hong Kong
Compared to hypomethylating agent alone, venetoclax plus hypomethylating agent benefits elderly patients with AML on overall survival and healthcare resource utilisation.
Authors
- Bonnie Kho
- Lai Wei (ORCID: https://orcid.org/0000-0003-1000-7559)
- Jiaqi Wang (ORCID: https://orcid.org/0009-0003-1863-9320)
- Raymond Wong (ORCID: https://orcid.org/0000-0002-9011-4268)
- Vivien Mak
- Chi Yeung Fung
- Xue Li (ORCID: https://orcid.org/0000-0003-4836-7808)
- June S. M. Lau
- Chung Yin Ha
- Qiuyun Fang
- Anskar Y.H. Leung (ORCID: https://orcid.org/0000-0001-9975-8687)
Institutions
- Chinese University of Hong Kong (HK)
- Tuen Mun Hospital (CN)
- Queen Mary Hospital (CN)
- Hong Kong Science and Technology Parks Corporation (HK)
- Kwai Chung Hospital (CN)
- Pamela Youde Nethersole Eastern Hospital (CN)
- Prince of Wales Hospital (CN)
- Queen Elizabeth Hospital (CN)
- University of Hong Kong (HK)
Publication Details
- Journal
- Therapeutic Advances in Hematology
- Published
- 2025-07-01
- DOI
- https://doi.org/10.1177/20406207251346914
- Citations
- 2
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 3.54